Our curriculum is purpose-built, offering more than just a series of meet-and-greets or a traditional road show. If you’re looking for networking sessions with broad innovation or investment groups that may not align with your industry, this isn’t that program. Instead, we focus on strategic, industry-specific connections and actionable insights tailored to help founders achieve meaningful US market traction.
As one US Market Access alum put it, “It wasn’t just the information the Science Center shared, but the connections they were able to facilitate made this trip worthwhile. We expected the classic ‘meet the investors’ road show, but this program introduced us not only to investors, but all the stakeholders involved in the healthcare system which was even more valuable.”
For example, Tal Shapsa Heiman, CEO of Epilog and a US Market Access alum, recently launched a pilot with Duke Health System to provide a patient-centric companion for end-of-life care. She credits the Science Center’s program for helping Epilog navigate the intricacies of securing clinical pilots in the US.
"We learned a lot about the complexity of multiple stakeholders involved in securing a clinical pilot," Heiman said, "including considerations around IRB (Institutional Review Board) approval, which was invaluable when working with Duke."
SpotitEarly, another US Market Access alumnus, provides a strong example. In 2024, the company launched a clinical trial at the University of Pennsylvania to test the accuracy of its AI-enhanced, multi-cancer screening technology for early breast cancer detection. Cofounder and COO Udi Bobrovsky and Vice President of Business Development Shomi Madar credit the Science Center with guiding the company through its early entrance to the US and most importantly, making the connection with the University of Pennsylvania that led to the company securing the clinical trial.
"Identifying a US-based partner for a pilot is just the start of a complex journey. The IRB submission, review, and revision process alone can take 12—24 months, demanding patience and perseverance," said Baumlin. "At the Science Center, we prepare startups with the essential knowledge and practical insights into what it truly takes to commercialize in the US."
This large, varied population also means customer discovery must be done at scale. The Science Center emphasizes understanding the needs of various patient groups, addressing specific health disparities, and tailoring messaging to resonate with different demographics. For example, chronic conditions like diabetes and hypertension have higher prevalence rates in certain regions and demographics, shaping both patient needs and the value proposition for health innovations.
Entering the US healthcare market is not just about proving traction upon entrance — it’s about proving fit once here. The Science Center’s approach combines industry insight, clinical partnerships, and strategic guidance to help founders gain the understanding and relationships they need to succeed. By prioritizing clinical credibility and customer discovery from the outset, we set companies up not only to enter the US market but to thrive within it.
Interested in learning more about the Science Center’s US Market Access Program? They’re seeking medtech, device, diagnostic, and digital health companies that have proven traction in their country of origin — and with recruitment partners to help source and vet companies for the program. Get in touch.